Mustafa Yılmaz1, Can Özlü2, Sevil Alkan3, Hasan Hüseyin Gümüşçü4

1Department of Infectious Diseases and Clinical Microbiology, Kütahya Health Sciences University, Evliya Çelebi Training and Research Hospital, Kütahya, Turkey
2Department of Internal Medicine, Kütahya Health Sciences University, Faculty of Medicine, Hematology, Kütahya, Turkey
3Department of Infectious Diseases and Clinical Microbiology, Çanakkale Onsekiz Mart University, Faculty of Medicine, Çanakkale, Turkey
4Department of Internal Medicine, Kütahya University of Health Sciences, Evliya Çelebi Training and Research Hospital, Kütahya, Turkey

Keywords: COVID-19, heparin-induced thrombocytopenia, heparin-induced thrombocytopenia.


Objectives: The purpose of this study was to evaluate the literature in terms of heparin-induced thrombocytopenia (HIT) that develops in COVID-19 patients.

Materials and methods: Between March 2019 and March 2021, all published articles on the subject of the study formed the target population of the study. The keywords "COVID-19" or "SARS-CoV-2" and "heparin-induced thrombocytopenia" were searched in English in the most prestigious databases of PubMed, Scopus, and Web of Science (WoS).

Results: No publications on this subject were found in the SCOPUS database. Only 13 publications were found in the PubMed database, and 11 in the WoS database. Eleven (78.5%) were published in 2020, and three (21.5%) were published in the first three months of 2021. There were four (28.5%) letters to the editor, six (42.8%) case reports, and one each (7.2%) correspondence, review, research article, and a short report. The only research article is also a retrospective study, except that no large case series or research article other than this one was found. The United States was identified as the country with the highest number of publications on this subject (57.1%).

Conclusion: Prospective studies, we believe, are urgently needed to understand the effects of heparin-induced thrombocytopenia development on morbidity, mortality, and long-term outcomes, a condition that can contribute to COVID-19 patient mortality as well as increased risk for thromboembolic events.

Cite this article as: Yılmaz M, Özlü C, Alkan S, Gümüşçü HH. COVID-19 and heparin-induced thrombocytopenia: Is there a relationship? D J Med Sci 2022;8(1):1-4.
Data Sharing Statement: The data that support the findings of this study are available from the corresponding author upon reasonable request.

Author Contributions

Idea/concept: M.Y., S.A.; design, control/supervision: M.Y., C.Ö., S.A.; data collection and/or processing: M.Y., C.Ö., S.A., H.H.G.; analysis and/or interpretation: S.A., M.Y., H.H.G.; literature review: S.A., H.H.G.; writing the article: M.Y., C.Ö., S.A., H.H.G.; critical review: S.A.; materials: S.A., C.Ö., H.H.G.

Conflict of Interest

The authors declared no conflicts of interest with respect to the authorship and/ or publication of this article.

Financial Disclosure

The authors received no financial support for the research and/or authorship of this article.